Bitterman Kevin 4

4 · Disc Medicine, Inc. · Filed Jun 23, 2026

AI-generated summary of this filing

Updated Jun 23, 2026

Disc Medicine (IRON) Director Kevin Bitterman Receives Option Grant

What Happened

Kevin Bitterman, a director of Disc Medicine, was granted a derivative award covering 6,212 shares on 2026-06-18. The grant is reported at $0.00 per share (total reported value $0) and is recorded as an award/other acquisition (derivative), not an open-market purchase or sale.

Key Details

Transaction date: 2026-06-18; Report filed: 2026-06-23.
Transaction type/code: Award/Grant (A); 6,212 shares @ $0.00 (derivative).
Shares owned after transaction: not specified in the provided filing excerpt.
Vesting: The underlying shares vest upon the earlier of (i) the Company's 2027 annual meeting or (ii) the one-year anniversary of the grant date, subject to continued service (footnote F1).
Ownership/beneficial interest: Proceeds from any sale of shares issued on exercise will be transferred to Atlas Venture Life Science Advisors, LLC; Bitterman disclaims ownership for Section 16 purposes except for any pecuniary interest (footnote F2).

Context

This filing reports a time/service-based equity award (derivative). It does not indicate any immediate sale or cashless exercise of shares. For retail investors, awards to directors are common for compensation and retention; they differ from purchases in signaling direct personal capital deployment.

Form 4

Period: 2026-06-18

Director

Transactions

Award
Stock Option (Right to Buy)
[F1][F2]
2026-06-18+6,212→ 6,212 total
Exercise: $70.79Exp: 2036-06-17→ Common Stock (6,212 underlying)

Footnotes (2)

[F1]The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.
[F2]This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Signature

/s/ Ommer Chohan, Attorney-in-Fact|2026-06-23

1 file